Product Description: Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC)[1].
Applications: Cancer-programmed cell death
Formula: C17H12F3NO4S
References: [1]Xu R, et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem. 2019 Aug 8;62(15):6876-6893.
CAS Number: 1672668-24-4
Molecular Weight: 383.34
Compound Purity: 99.85
Research Area: Cancer
Solubility: Acetone : 50 mg/mL (ultrasonic)/DMSO : 50 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: HIF/HIF Prolyl-Hydroxylase
English
Deutsch
